Response to "Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidence"

Author(s):: Groenland, S.L.; Geel, D.R.; Beijnen, J.H.; Smit, E.F.; Huitema, A.D.R.; Steeghs, N.

Published: 2021
Publication type: Article / Letter to editor

Date issued: 2021-08-13
Language: English
Publisher: WILEY
Is part of: Clinical Pharmacology and Therapeutics
hdl: 1887/3274093
doi: 10.1002/cpt.2372